For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

The risk for both self-reported and symptomatic flare in inflammatory bowel disease is associated with psychosocial factors, ...

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...

FAECAL microbiota transplantation (FMT) shows promise in treating ulcerative colitis (UC), with specific gut microbial ...

A new study published in BMC Gastroenterology identified that patients with inflammatory bowel disease (IBD), such as Crohn's ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

That basic concept is why tons of people on social media are posting about a viral new product: Coconut Cult’s chocolate ...

Specialists from the Digestive System Department at Hospital Germans Trias have conducted and published a unique study that ...

Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million ...

During respiratory illness season there a more graphic, yet shorter-lasting virus making the rounds especially among kids: ...